Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults
Completed
Department of Health and Human Services
Phase 1
2010-12-01
The purpose of this Phase 1 clinical trial is to evaluate the safety, tolerability, and
immunogenicity of AV7909 anthrax vaccine in healthy adults. In this study, healthy male and
female subjects between 18 and 50 years of age will receive vaccinations via the
intramuscular (IM) route at Days 0 and 14. Safety and tolerability will be evaluated via
laboratory tests, physical examinations, vital signs, adverse events (AEs), concomitant
medications, and local and systemic signs and symptoms of reactogenicity.
Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults
Completed
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 1
2010-12-01
The purpose of this Phase 1 clinical trial is to evaluate the safety, tolerability, and
immunogenicity of AV7909 anthrax vaccine in healthy adults. In this study, healthy male and
female subjects between 18 and 50 years of age will receive vaccinations via the
intramuscular (IM) route at Days 0 and 14. Safety and tolerability will be evaluated via
laboratory tests, physical examinations, vital signs, adverse events (AEs), concomitant
medications, and local and systemic signs and symptoms of reactogenicity.
Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults
Completed
Emergent BioSolutions
Phase 1
2010-12-01
The purpose of this Phase 1 clinical trial is to evaluate the safety, tolerability, and
immunogenicity of AV7909 anthrax vaccine in healthy adults. In this study, healthy male and
female subjects between 18 and 50 years of age will receive vaccinations via the
intramuscular (IM) route at Days 0 and 14. Safety and tolerability will be evaluated via
laboratory tests, physical examinations, vital signs, adverse events (AEs), concomitant
medications, and local and systemic signs and symptoms of reactogenicity.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.